• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » October 2012 – The CenterWatch Monthly : PDF
October 2012 – The CenterWatch Monthly : PDF

October 2012 – The CenterWatch Monthly : PDF

$79.00

Product Details

CRCs workload up: relative pay declining

Clinical research coordinators (CRCs), widely considered the “glue” that holds clinical projects together at investigative sites, report that the volume of studies they manage on an annual basis has nearly doubled during the past decade, yet salary levels during this same period have remained flat, according to a new CenterWatch survey. Nearly 70% of the 269 study coordinators who participated in the survey—the first new CenterWatch analysis of the CRC workforce in a decade—also report a significant increase in their responsibilities, as clinical studies have become more complex and budget constraints have taken a toll on investigative sites. Surprisingly, despite this increasing workload, the turnover rate among CRCs has…

As IRB industry grows up, consolidation comes knocking

As various unforgiving market forces sweep through all sectors of the drug development world, we’ve seen some interesting changes in the IRB space in the last year. These shifts represent the various ways in which consolidation is now sweeping through the small but vital sector of the research enterprise, according to noted bioethicist Art Caplan. There’s the IRB closing, the IRB acquired by another IRB and the IRB purchased by an investor group…

Eye On: Boehringer Ingelheim

Boehringer Ingelheim is a globally affiliated group of 145 companies founded and headquartered in Germany. Currently, it employs more than 44,000, including 7,000 in research and development. To design new therapies for diseases with an unmet therapeutic need, Boehringer Ingelheim focuses heavily on R&D, not only internally but also through external collaborations…

  • The evolution of MSLs
  • Pharmaceutical innovation in China
  • Regulatory Update
  • Month in Review
  • CRO Industry Update
  • Study Lead Opportunities
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing